# IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Canonical URL: https://biopharmsignal.com/news/INAB/in8bio-expands-inb-100-phase-1-clinical-trial-with-addition-of-the-ohio-state-university-as-new-site
Ticker: INAB
Company: IN8bio
Source: IN8bio
Published: 2025-10-29 12:00 EST
Original Source URL: https://investors.in8bio.com
## Summary

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the

## Article Body
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the
## Recent Company News
- 2026-06-03 12:30 EST — [IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies](https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-t-cell-engineering-and-combination-therapies) — Source: IN8bio
- 2026-06-01 12:30 EST — [IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026](https://biopharmsignal.com/news/INAB/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026) — Source: IN8bio
- 2026-05-14 12:00 EST — [IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma](https://biopharmsignal.com/news/INAB/in8bio-presents-new-translational-data-demonstrating-deltex-dri-reshapes-the-immune-landscape-in-glioblastoma) — Source: IN8bio
- 2026-05-07 20:30 EST — [IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/INAB/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights) — Source: IN8bio
- 2026-05-06 12:00 EST — [IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences](https://biopharmsignal.com/news/INAB/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-randd-day-and-medical-conferences) — Source: IN8bio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)